Ciprofloxacin

Ciprofloxacin

SCHEMBL1661044

O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O.[H+]

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

gyrAgyrBparCparE

The experimentally established mechanism targets of Ciprofloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.98
▸ ALDH1A1 P00352 6/20 0.98
▸ LMNA P02545 5/20 0.98
▸ HPGD P15428 4/20 0.98
▸ HSD17B10 Q99714 4/20 0.98
▸ CYP1A2 P05177 1/20 0.98
▸ TOP2A P11388 1/20 0.98
▸ CYP2C9 P11712 1/20 0.98
▸ TOP2B Q02880 1/20 0.98
▸ MAPT P10636 1/20 0.71
▸ HTT P42858 2/20 0.66
▸ BRD4 O60885 1/20 0.66
▸ TSHR P16473 1/20 0.66
▸ CYP2J2 P51589 1/20 0.66
▸ NPSR1 Q6W5P4 1/20 0.66
▸ PIK3CG P48736 7/20 0.61
▸ PIK3CD O00329 5/20 0.61
▸ PIK3R1 P27986 5/20 0.61
▸ PIK3CA P42336 5/20 0.61
▸ SMN1; SMN2 Q16637 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ciprofloxacin SCHEMBL27818693 0.99 KDM4E (0.96) KDM4EALDH1A1LMNAHPGDHSD17B10
Ciprofloxacin SCHEMBL4459712 0.99 KDM4E (1.00) KDM4EALDH1A1LMNAHPGDHSD17B10
Ciprofloxacin SCHEMBL29137332 0.99 KDM4E (1.00) KDM4EALDH1A1LMNAHPGDHSD17B10
Ciprofloxacin SCHEMBL2325956 0.99 KDM4E (1.00) KDM4EALDH1A1LMNAHPGDHSD17B10
Ciprofloxacin SCHEMBL345730 0.99 KDM4E (1.00) KDM4EALDH1A1LMNAHPGDHSD17B10
Ciprofloxacin SCHEMBL2900 0.99 KDM4E (1.00) KDM4EALDH1A1LMNAHPGDHSD17B10
Ciprofloxacin SCHEMBL3667227 0.98 KDM4E (0.94) KDM4EALDH1A1LMNAHPGDHSD17B10
Ciprofloxacin SCHEMBL5617753 0.98 KDM4E (0.98) KDM4EALDH1A1LMNAHPGDHSD17B10
Ciprofloxacin SCHEMBL42310 0.98 KDM4E (0.98) KDM4EALDH1A1LMNAHPGDHSD17B10
Ciprofloxacin SCHEMBL2465661 0.98 KDM4E (0.98) KDM4EALDH1A1LMNAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230000802-A1 THERMORESPONSIVE HYDROGEL CONTAINING POLYMER MICROPARTICLES FOR CONTROLLED DRUG DELIVERY UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2023-01-05 — — US disclosed
CN-113713167-A Preparation and application of novel photothermal sensitive composite hydrogel dressing 长春工业大学 2021-11-30 — — CN disclosed
US-20210015770-A1 THERMORESPONSIVE HYDROGEL CONTAINING POLYMER MICROPARTICLES FOR CONTROLLED DRUG DELIVERY TO THE EAR UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-01-21 — — US disclosed
EP-3508197-A1 MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS Otonomy, Inc. (US) 2019-07-10 — — EP disclosed
WO-2019118330-A1 THERMORESPONSIVE HYDROGEL CONTAINING POLYMER MICROPARTICLES FOR CONTROLLED DRUG DELIVERY TO THE EAR UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2019-06-20 — — WO disclosed
US-20180125781-A1 MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS OTONOMY, INC. 2018-05-10 — — US disclosed
US-20120277199-A1 Modulation of Gel Temperature of Poloxamer-Containing Formulations OTONOMY, INC. (US) 2012-11-01 — — US disclosed
EP-2490722-A2 MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS Otonomy, Inc. (US) 2012-08-29 — — EP disclosed
WO-2011050206-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS OTONOMY, INC. (US) 2011-04-28 — — WO disclosed
WO-2011049960-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS OTONOMY, INC. (US) 2011-04-28 — — WO disclosed
WO-2011049958-A2 MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS OTONOMY, INC. (US) 2011-04-28 — — WO disclosed
EP-1124587-A1 HYDROGEL WOUND DRESSING CONTAINING LIPOSOME-ENCAPSULATED THERAPEUTIC AGENT Department of National Defence (CA) 2001-08-22 — — EP disclosed
WO-2001015750-A1 HYDROGEL WOUND DRESSING CONTAINING LIPOSOME-ENCAPSULATED THERAPEUTIC AGENT DEPARTMENT OF NATIONAL DEFENCE (CA) 2001-03-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180125781-A1 MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS PTGIR, HSPH1, HSP90AA1 KDM4E 4728/4885ALDH1A1 3364/4885LMNA 4109/4885
US-20120277199-A1 Modulation of Gel Temperature of Poloxamer-Containing Formulations PTGIR, HSPH1, HSP90AA1 KDM4E 4728/4885ALDH1A1 3364/4885LMNA 4109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback